Vascular StiffnessNRMNCT06345443
NRM on Vascular Perfusion in Healthy Adults
A study testing Nicotinamide Riboside Malate in people with Vascular Stiffness, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults. Read more about this study
- Who is it for?
- Ages 35 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Vascular Stiffness
- What is being tested?
- Nicotinamide Riboside Malate
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 25 Nov 2024to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- >= 35 and <=70
- Provides consent to participate in the study
- Not pregnant at time of consent
- Understands and agrees to follow all study procedures and limitations
- Have no contraindicating comorbid health condition as determined by the clinical investigators
Who cannot join
- Pregnant, nursing, or trying to conceive
- BMI Restrictions: <35
- Allergy or sensitivity to study agent ingredients
- Hypertension treated with medication
- Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
- Surgery planned during the course of the trial
Show all 10Show fewer
- History or past diagnosis of chronic diseases, unstable medical conditions, blood/bleeding disorders or stroke
- History or current diagnosis of cancer (except for successfully treated basal cell carcinoma diagnosed less than 5 years prior to screening or cancer in full remission more than 5 years after diagnosis.
- Abnormal blood chemistries for renal or liver function (defined as 1 standard deviation outside of the normal range), alcohol dependence, uncontrolled thyroid disease, severe obesity (body mass index >40 kg m-2), or weight stable for at least 3 months prior to enrolling in the study (defined as >2 kg change in body mass).
- An unstable medical or mental health condition as determined by the physician investigator.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
About this study
Official title: The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Healthy Adults: A Critical Foundation of Cerebrovascular Health, Cardiovascular Health, and Healthy Aging
The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.
Read the detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-dose clinical trial. Participants will be randomly assigned to one of three groups. Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.
- Conditions
- Vascular Stiffness
- Being tested
- Nicotinamide Riboside Malate, Placebo
- Keywords
- cardiovascular, Nicotinamide Riboside, Supplements, NRM
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nicotinamide Riboside MalateDietary supplement
Also called NRM
Active supplement.
PlaceboOther
Placebo
| Study group | Role | What they receive |
|---|---|---|
| 830 mg Nicotinamide and Placebo | Active comparator | 830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks Receives: Dietary Supplement: Nicotinamide Riboside Malate; Other: Placebo |
| 1660 mg Nicotinamide | Active comparator | 1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks Receives: Dietary Supplement: Nicotinamide Riboside Malate |
| Placebo | Placebo comparator | 2 identical Placebo capsules twice a day for 12 weeks Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Participants with Reduced Endothelial Stiffness
Endothelial Peripheral Arterial Tonometry testing will be used to assess endothelial stiffness changes over study
Measured: Baseline to End of study at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2024
- Study start25 Nov 2024
- Primary completion30 Sep 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular StiffnessStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ryan T. Hurt, M.D., Ph.D., Mayo Clinic
- Investigators
- Ryan Hurt, MD, PhD, Principal investigator, Mayo ClinicBrent Bauer, MD, Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06345443
- Sponsor's protocol ID
- 23-005288
- Acronym
- NRM
- Status last verified
- Mar 2026
- First submitted
- 28 Mar 2024
- Last updated
- 18 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of Oral Nicotinamide Riboside on Systemic Vascular Perfusion in Healthy Adults: A Critical Foundation of Cerebrovascular Health, Cardiovascular Health, and Healthy Aging
- ClinicalTrials.gov ID
- NCT06345443
- Acronym / sponsor ID
- NRM / 23-005288
- Conditions
- Vascular Stiffness
- Keywords
- cardiovascular, Nicotinamide Riboside, Supplements, NRM
- Study type
- Interventional
- Recruitment status
- Enrolling by invitation
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 25 Nov 2024 (actual)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 3 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to better understand the effects of nicotinamide riboside supplement in overall cardiovascular health in healthy adults.
Detailed description
This study is a randomized, double-blind, placebo-controlled, parallel-dose clinical trial. Participants will be randomly assigned to one of three groups. Study measurements will be completed at three timepoints and intervention taken daily throughout the subject's 12 weeks of participation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 830 mg Nicotinamide and Placebo | Active comparator | Dietary Supplement: Nicotinamide Riboside Malate, Other: Placebo830 mg Nicotinamide supplement capsule and 1 identical Placebo capsule twice a day for 12 weeks |
| 1660 mg Nicotinamide | Active comparator | Dietary Supplement: Nicotinamide Riboside Malate1660 mg Nicotinamide supplement; 2 of the 830 mg capsules twice a day for 12 weeks |
| Placebo | Placebo comparator | Other: Placebo2 identical Placebo capsules twice a day for 12 weeks |
Who may qualify
- Ages
- 35 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- >= 35 and <=70
- Provides consent to participate in the study
- Not pregnant at time of consent
- Understands and agrees to follow all study procedures and limitations
- Have no contraindicating comorbid health condition as determined by the clinical investigators
Key exclusion criteria (10 listed)
- Pregnant, nursing, or trying to conceive
- BMI Restrictions: <35
- Allergy or sensitivity to study agent ingredients
- Hypertension treated with medication
- Use of natural health products containing nicotinamide riboside, quercetin, trans-resveratrol, or betaine anhydrous within 7 days prior to randomization and during the course of the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nicotinamide Riboside MalateAlso: NRMActive supplement. | Dietary supplement | 1660 mg Nicotinamide, 830 mg Nicotinamide and Placebo |
| PlaceboPlacebo | Other | 830 mg Nicotinamide and Placebo, Placebo |
Primary outcome
Number of Participants with Reduced Endothelial Stiffness
Time frame: Baseline to End of study at 12 weeks
Endothelial Peripheral Arterial Tonometry testing will be used to assess endothelial stiffness changes over study
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Vascular Stiffness
Recruiting
NightWare and Cardiovascular Health in Women With PTSD
Post Traumatic Stress Disorder, Cardiovascular Diseases
Active, not recruitingPhase 2
Effect of Equol Supplementation on Arterial Stiffness and Cognition in Healthy Volunteers
Arterial Stiffness, White Matter Lesions
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
Not yet recruitingEarly Phase 1
Early Botulinum Toxin for Muscle Stiffness Reduction in First-Time Stroke Patients: Improving Recovery and Independence
Spasticity, Stroke
RecruitingObservational study
Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ryan Hurt, MD, PhD principal investigator
Mayo Clinic
Brent Bauer, MD principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Nicotinamide Riboside Malate in people with Vascular Stiffness, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 18 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Participants with Reduced Endothelial Stiffness (time frame: Baseline to End of study at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2026.